Novel investigational therapies for treating pulmonary arterial hypertension

References

Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.

• Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62:D100–D108.
   PubMed Web of Science ®Google Scholar
• Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med. 2004;351:1655–1665.
   PubMed Web of Science ®Google Scholar
• Benza RL, Miller DP, Barst RJ, et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest. 2012;142:448–456.
   PubMed Web of Science ®Google Scholar

• REVEAL and French Registries that provide information about survival in the current era.

• Humbert M, Sitbon O, Yaici A, et al. French pulmonary arterial hypertension network. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J. 2010;36:549–555.
   PubMed Web of Science ®Google Scholar
• Olschewski H. Prostacyclins. In: Pharmacotherapy of pulmonary hypertension. Berlin: Springer; 2013. p. 177–198.
   Google Scholar
• Coleman RA, Smith WL, Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev. 1994;46(2):205–229.
   PubMed Web of Science ®Google Scholar
• Olschewski H, Olschewski A, Rose F, et al. Physiologic basis for the treatment of pulmonary hypertension. J Lab Clin Med. 2001;138:287–297.
   PubMed Web of Science ®Google Scholar
• Wise H. Multiple signalling options for prostacyclin. Acta Pharmacol Sin. 2003;24:625–630.
   PubMed Web of Science ®Google Scholar
• Billington CK, Penn RB. Signaling and regulation of G protein-coupled receptors in airway smooth muscle. Respir Res. 2003;4:1–23.
   PubMed Web of Science ®Google Scholar
• Chow KB, Jones RL, Wise H. Protein kinase A-dependent coupling of mouse prostacyclin receptors to Gi is cell-type dependent. Eur J Pharmacol. 2003;474:7–13.
   PubMed Web of Science ®Google Scholar
• Tang B, Li Y, Nagaraj C, et al.Endothelin-1 inhibits background two-pore domain channel TASK-1 in primary human pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol. 2009;41:476–483.
   PubMed Web of Science ®Google Scholar
• Li Y, Connolly M, Nagaraj C, et al. Peroxisome proliferator-activated receptor-beta/delta, the acute signaling factor in prostacyclin-induced pulmonary vasodilation. Am J Respir Cell Mol Biol. 2012;46:372–379.
   PubMed Web of Science ®Google Scholar
• Mubarak KK. A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension. Respir Med. 2010;104:9–21.
   PubMed Web of Science ®Google Scholar
• Kuwano K, Hashino A, Asaki T, et al. NS-304, an orally available and long-acting prostacyclin receptor agonist prodrug. J Pharmacol Exp Ther. 2007;322:1181–1188.
   PubMed Web of Science ®Google Scholar
• Simonneau G, Torbicki A, Hoeper MM, et al. Selexipag, an oral, selective IP receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J. 2012;40:874–880.
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Channick R, Chin K, et al. Effect of selexipag on morbidity/mortality in pulmonary arterial hypertension: results of the GRIPHON study. JACC. 2015;65(10S):A1538.
   Google Scholar
• Morrell NW, Archer SL, Defelice A, et al. Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension. Pulm Circ. 2013;3(1):226.
   PubMedGoogle Scholar
• Indolfi C, Avvedimento EV, Di Lorenzo E, et al. Activation of cAMP-PKAsignaling in vivo inhibits smooth muscle cell proliferation induced by vascular injury. Nat Med. 1997;3(7):775–779.
   PubMed Web of Science ®Google Scholar
• Chen ZS, Lee K, Kruh GD. Transport of cyclic nucleotides and estradiol 17-beta-Dglucuronideby multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. J Biol Chem. 2001;276(36):33747–33754.
   PubMed Web of Science ®Google Scholar
• Lincoln TM, Dey N, Sellak H. cGMP-dependent protein kinase signaling mechanisms in smooth muscle: from the regulation of tone to gene expression. J Appl Physiol. 2001;91(3):1421–1430.
   PubMed Web of Science ®Google Scholar
• Wharton J, Davie N, Upton PD, et al. Prostacyclin analogues differentially inhibit growth of distal and proximal human pulmonary artery smooth muscle cells. Circulation. 2000;102(25):3130–3136.
   PubMed Web of Science ®Google Scholar
• Yokochi A, Itoh H, Maruyama J, et al. Colforsin-induced vasodilation in chronic hypoxic pulmonary hypertension in rats. J Anesth. 2010;24(3):432–440.
   PubMed Web of Science ®Google Scholar
• Schermuly RT, Pullamsetti SS, Kwapiszewska G, et al. Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy. Circulation. 2007;115(17):2331–2339.
   PubMed Web of Science ®Google Scholar
• Crosswhite P, Zhongjie S. Inhibition of phosphodiesterase-1 attenuates cold-induced pulmonary hypertension. Hypertension. 2013;61(3):585–592.
   PubMed Web of Science ®Google Scholar
• Evgenov OV, Busch CJ, Evgenov NV, et al. Inhibition of phosphodiesterase 1 augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs with acute pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2006;290(4):L723–L729.
   PubMed Web of Science ®Google Scholar
• Sassi Y, Abi-Gerges A, Fauconnier J, et al. Regulation of cAMP homeostasis by the efflux protein MRP4 in cardiac myocytes. FASEB J. 2012;26(3):1009–1017.
   PubMed Web of Science ®Google Scholar
• Sassi Y, Hulot J. Pulmonary hypertension: novel pathways and emerging therapies inhibitors of cGMP and cAMP metabolism. In Pharmacotherapy of pulmonary hypertension. Berlin: Springer; 2013. p. 513–529.
   Google Scholar
• Hara Y, Sassi Y, Guibert C, et al. Inhibition of MRP4 prevents and reverses pulmonary hypertension in mice. J Clin Invest. 2011;121(7):2888–2897.
   PubMed Web of Science ®Google Scholar
• Ahluwalia A, MacAllister RJ, Hobbs AJ. Vascular actions of natriuretic peptides. Cyclic GMP-dependent and -independent mechanisms. Basic Res Cardiol. 2004;99:83–89.
   PubMed Web of Science ®Google Scholar
• de Bold AJ, Borenstein HB, Veress AT, et al. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci. 1981;28:89–94.
   PubMed Web of Science ®Google Scholar
• Hobbs AJ. Soluble guanylate cyclase: the forgotten sibling. Trends Pharmacol Sci. 1997;18:484–491.
   PubMed Web of Science ®Google Scholar
• Casserly B, Klinger JR. Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent. Drug Des Dev Ther. 2009;3:269–287.
   PubMed Web of Science ®Google Scholar
• Potter LR, Abbey-Hosch S, Dickey DM. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev. 2006;27(1):47–72.
   PubMed Web of Science ®Google Scholar
• Bianchi C, Gutkowska J, Thibault G, et al. Radioautographic localization of 125I-atrial natriuretic factor (ANF) in rat tissues. Histochemistry. 1985;82:441–452.
   PubMedGoogle Scholar
• Gutkowska J, Cantin M, Genest J, et al. Release of immunoreactive atrial natriuretic factor from the isolated perfused rat lung. FEBS Lett. 1987;214:17–20.
   PubMed Web of Science ®Google Scholar
• Gutkowska J, Nemer M. Structure, expression, and function of atrial natriuretic factor in extraatrial tissues. Endocr Rev. 1989;10:519–536.
   PubMed Web of Science ®Google Scholar
• Sakamoto M, Nakao K, Morii N, et al. The lung as a possible target organ for atrial natriuretic polypeptide secreted from the heart. Biochem Biophys Res Commun. 1986;135:515–520.
   PubMed Web of Science ®Google Scholar
• Tallerico-Melnyk T, Yip CC, Watt VM. Widespread co-localization of mRNAs encoding the guanylate cyclase-coupled natriuretic peptide receptors in rat tissues. Biochem Biophys Res Commun. 1992;189:610–616.
   PubMed Web of Science ®Google Scholar
• Toshimori H, Nakazato M, Toshimori K, et al. Distribution of atrial natriuretic polypeptide (ANP)-containing cells in the rat heart and pulmonary vein. Immunohistochemical study and radioimmunoassay. Cell Tissue Res. 1988;251:541–546.
   PubMed Web of Science ®Google Scholar
• Angus RM, McCallum MJ, Hulks G, et al. Bronchodilator, cardiovascular, and cyclic guanylyl monophosphate response to high-dose infused atrial natriuretic peptide in asthma. Am Rev Respir Dis. 1993;147:1122–1125.
   PubMed Web of Science ®Google Scholar
• Baliga RS, Zhao L, Madhani M, et al. Synergy between natriuretic peptides and phosphodiesterase 5 inhibitors ameliorates pulmonary arterial hypertension. Am J Respir Crit Care Med. 2008;178:861–869.
   PubMed Web of Science ®Google Scholar
• Klinger JR, Houtchens J, Thaker S, et al. Acute cardiopulmonary hemodynamic effects of brain natriuretic peptide in patients with pulmonary arterial hypertension. Chest. 2005;128:618S–619S.
   PubMed Web of Science ®Google Scholar
• Klinger JR, Thaker S, Houtchens J, et al. Pulmonary hemodynamic responses to brain natriuretic peptide and sildenafil in patients with pulmonary arterial hypertension. Chest. 2006;129:417–425.
   PubMed Web of Science ®Google Scholar

• Nesiritide, a recombinant BNP, augments sildenafil in PAH patients.

• Michaels AD, Chatterjee K, DeMarco T. Effects of intravenous nesiritide on pulmonary hemodynamics in pulmonary hypertension. J Card Fail. 2005;11.6:425–431.
   Web of Science ®Google Scholar
• Andreassen AK, Wergeland R, Simonsen S, et al. N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension. Am J Cardiol. 2006;98:528–529.
   Web of Science ®Google Scholar
• Ishihara T, Nakamura S, Kaziro Y, et al. Molecular cloning and expression of a cDNA encoding the secretin receptor. EMBO J. 1991;10:1635–1641.
   PubMed Web of Science ®Google Scholar
• Inagaki N, Yoshida H, Mizuta M, et al. Cloning and functional characterization of a third pituitary adenylate cyclase-activating polypeptide receptor subtype expressed in insulin-secreting cells. Proc Natl Acad Sci USA. 1994;91:2679–2683.
   PubMed Web of Science ®Google Scholar
• Lutz EM, Sheward WJ, West KM, et al. The VIP2 receptor: molecular characterization of a cDNA encoding a novel receptor for vasoactive intestinal peptide. FEBS Lett. 1993;334:3–8.
   PubMed Web of Science ®Google Scholar
• Baliga RA, MacAllister RJ, Hobbs AJ. Vasoactive peptides and the pathogenesis of pulmonary hypertension: role and potential therapeutic application In: Pharmacotherapy of pulmonary hypertension. Berlin: Springer; 2013. p. 477–511.
   Google Scholar
• Said SI, Hamidi SA, Dickman KG, et al. Moderate pulmonary arterial hypertension in male mice lacking the vasoactive intestinal peptide gene. Circulation. 2007;115:1260–1268.
   PubMed Web of Science ®Google Scholar
• Hamidi SA, Prabhakar S, Said SI. Enhancement of pulmonary vascular remodeling and inflammatory genes with VIP gene deletion. Eur Respir J. 2008;31:135–139.
   PubMed Web of Science ®Google Scholar
• Petkov V, Mosgoeller W, Ziesche R, et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest. 2003;111:1339–1346.
   PubMed Web of Science ®Google Scholar
• Leuchte HH, Baezner C, Baumgartner RA, et al. Inhalation of vasoactive intestinal peptide in pulmonary hypertension. Eur Respir J. 2008;32:1289–1294.
   PubMed Web of Science ®Google Scholar
• Galie N, Boonstra A, Ewert R, et al. Effects of inhaled aviptadil (vasoactive intestinal peptide) in patients with pulmonary arterial hypertension (PAH). Am J Respir Crit Care Med. 2010;181:A2516.
   Web of Science ®Google Scholar
• McMurray JJ, Packer M, Desai AS, et al. Angiotensin-Neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004.
   PubMed Web of Science ®Google Scholar
• Thompson JS, Sheedy W, Morice AH. Neutral endopeptidase (NEP) inhibition in rats with established pulmonary hypertension secondary to chronic hypoxia. Br J Pharmacol. 1994;113:1121–1126.
   PubMed Web of Science ®Google Scholar
• Sumitomo M, Iwase A, Zheng R, et al. Synergy in tumor suppression by direct interaction of neutral endopeptidase with PTEN. Cancer Cell. 2004;5:67–78.
   PubMed Web of Science ®Google Scholar
• Cohen AJ, Bunn PA, Franklin W, et al. Neutral endopeptidase: variable expression in human lung, inactivation in lung cancer, and modulation of peptide-induced calcium flux. Cancer Res. 1996;56:831–839.
   PubMed Web of Science ®Google Scholar
• Dempsey EC, Wick MJ, Karoor V, et al. Neprilysin null mice develop exaggerated pulmonary vascular remodeling in response to chronic hypoxia. Am J Pathol. 2009;174(3):782–796.
   PubMed Web of Science ®Google Scholar
• Karoor V, Oka M, Walchak SJ, et al. Neprilysin regulates pulmonary artery smooth muscle cell phenotype through a PDGF receptor dependent mechanism. Hypertension. 2013;61(4):921–930.
   PubMed Web of Science ®Google Scholar
• Heaton J, Lin B, Chang JK, et al. Pulmonary vasodilation to adrenomedullin: a novel peptide in humans. Am J Physiol. 1995;268:H2211–H2215.
   PubMed Web of Science ®Google Scholar
• Lippton H, Chang JK, Hao Q, et al. Adrenomedullin dilates the pulmonary vascular bed in vivo. J Appl Physiol. 1994;76:2154–2156.
   PubMed Web of Science ®Google Scholar
• Kakishita M, Nishikimi T, Okano Y, et al. Increased plasma levels of adrenomedullin in patients with pulmonary hypertension. Clin Sci (Lond). 1999;96:33–39.
   PubMed Web of Science ®Google Scholar
• Nishikimi T, Nagata S, Sasaki T, et al. Plasma concentrations of adrenomedullin correlate with the extent of pulmonary hypertension in patients with mitral stenosis. Heart. 1997;78:390–395.
   PubMed Web of Science ®Google Scholar
• Shimokubo T, Sakata J, Kitamura K, et al. Augmented adrenomedullin concentrations in right ventricle and plasma of experimental pulmonary hypertension. Life Sci. 1995;57:1771–1779.
   PubMed Web of Science ®Google Scholar
• Yoshibayashi M, Kamiya T, Kitamura K, et al. Plasma levels of adrenomedullin in primary and secondary pulmonary hypertension in patients <20 years of age. Am J Cardiol. 1997;79:1556–1558.
   PubMed Web of Science ®Google Scholar
• Ando K, Fujita T. Lessons from the adrenomedullin knockout mouse. Regul Pept. 2003;112:185–188.
   PubMed Web of Science ®Google Scholar
• Matsui H, Shimosawa T, Itakura K, et al. Adrenomedullin can protect against pulmonary vascular remodeling induced by hypoxia. Circulation. 2004;109:2246–2251.
   PubMed Web of Science ®Google Scholar
• Nagaya N, Nishikimi T, Uematsu M, et al. Haemodynamic and hormonal effects of adrenomedullin in patients with pulmonary hypertension. Heart. 2000;84:653–658.
   PubMed Web of Science ®Google Scholar
• Nagaya N, Miyatake K, Kyotani S, et al. Pulmonary vasodilator response to adrenomedullin in patients with pulmonary hypertension. Hypertens Res. 2003;26(Suppl):S141–S146.
   PubMed Web of Science ®Google Scholar
• Nagaya N, Kyotani S, Uematsu M, et al. Effects of adrenomedullin inhalation on hemodynamics and exercise capacity in patients with idiopathic pulmonary arterial hypertension. Circulation. 2004;109:351–356.
   PubMed Web of Science ®Google Scholar
• Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43(12 Suppl):13S–24S.
   PubMed Web of Science ®Google Scholar
• Morrell NW, Adnot S, Archer SL, et al. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(1 Suppl):S20–S31.
   PubMed Web of Science ®Google Scholar
• Humbert M, Monti G, Fartoukh M, et al. Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J. 1998;11:554–559.
   PubMed Web of Science ®Google Scholar
• Perros F, Montani D, Dorfmuller P, et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2008;178(1):81–88.
   PubMed Web of Science ®Google Scholar
• Montani D, Perros F, Gambaryan N, et al. C-kit-positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2011;184:116–123.
   PubMed Web of Science ®Google Scholar
• Dahal BK, Heuchel R, Pullamsetti SS, et al. Hypoxic pulmonary hypertension in mice with constitutively active platelet-derived growth factor receptor-β. Pulm Circ. 2011;1.2:259–268.
   Google Scholar
• Schermuly RT, Dony E, Ghofrani HA, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest. 2005;115:2811–2821.
   PubMed Web of Science ®Google Scholar
• Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev. 1999;79:1283–1316.
   PubMed Web of Science ®Google Scholar
• Kazlauskas A. Receptor tyrosine kinases and their targets. Curr Opin Genet Dev. 1994;4:5–14.
   PubMed Web of Science ®Google Scholar
• Rosenkranz S, Kazlauskas A. Evidence for distinct signaling properties and biological responses induced by the PDGF receptor α and β subtypes. Growth Factors. 1999;16:201–216.
   PubMed Web of Science ®Google Scholar
• Graf K, Xi XP, Yang D, et al. Mitogen-activated protein kinase activation is involved in platelet-derived growth factor-directed migration by vascular smooth muscle cells. Hypertension. 1997;29:334–339.
   PubMed Web of Science ®Google Scholar
• Heldin CH, Ostman A, Ronnstrand L. Signal transduction via platelet-derived growth factor receptors. Biochim Biophys Acta. 1998;1378:F79–F113.
   PubMed Web of Science ®Google Scholar
• Kappert K, Peters KG, Bohmer FD, et al. Tyrosine phosphatases in vessel wall signaling. Cardiovasc Res. 2005;65:587–598.
   PubMed Web of Science ®Google Scholar
• Kappert K, Paulsson J, Sparwel J, et al. Dynamic changes in the expression of DEP-1 and other PDGF receptor-antagonizing PTPs during onset and termination of neointima formation. FASEB J. 2007;21:523–534.
   PubMed Web of Science ®Google Scholar
• Ten Freyhaus H, Dagnell M, Leuchs M, et al. Hypoxia enhances platelet-derived growth factor signaling in the pulmonary vasculature by down-regulation of protein tyrosine phosphatases. Am J Respir Crit Care Med. 2011;183:1092–1102.
   PubMed Web of Science ®Google Scholar
• Berghausen E, ten Freyhaus H, Rosenkranz S. Targeting of platelet-derived growth factor signaling in pulmonary arterial hypertension. In: Pharmacotherapy of pulmonary hypertension. Berlin: Springer; 2013. p. 381–408.
   Google Scholar
• Redner RL. Why doesn’t imatinib cure chronic myeloid leukemia? Oncologist. 2010;15:182–186.
   PubMed Web of Science ®Google Scholar
• Patterson KC, Weissmann A, Ahmadi T, et al. Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. Ann Intern Med. 2006;145:152–153.
   PubMed Web of Science ®Google Scholar
• Ten Freyhaus H, Dumitrescu D, Berghausen E, et al. Imatinib mesylate for the treatment of pulmonary arterial hypertension. Expert Opin Investig Drugs. 2012;21(1):119–134.
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Morrell NW, Hoeper MM, et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med. 2010;182:1171–1177.
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Barst RJ, Bourge RC, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation. 2013;127(10):1128–1138.
   PubMed Web of Science ®Google Scholar
• Shah AM, Campbell P, Rocha GQ, et al. Effect of imatinib as add-on therapy on echocardiographic measures of right ventricular function in patients with significant pulmonary arterial hypertension. Eur Heart J. 2015;36(10):623–632.
   PubMed Web of Science ®Google Scholar

• IMPRES trial: Imatinib improved hemodynamics and 6MWD, but the side effects were intolerable.

• Montani D, Bergot E, Gunther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012;125(17):2128–2137.
   PubMed Web of Science ®Google Scholar
• Efficacy, safety, tolerability and pharmacokinetics (PK) of nilotinib (AMN107) in pulmonary arterial hypertension (PAH). http://clinicaltrials.gov/ct2/show/NCT01179737
   Google Scholar
• Strumberg D, Richly H, Hilger RA, et al. Phase 1 clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol. 2005;23:965–972.
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099–7109.
   PubMed Web of Science ®Google Scholar
• Gomberg-Maitland M, Maitland ML, Barst RJ, et al. A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension. Clin Pharmacol Ther. 2010;87(3):303–310.
   PubMed Web of Science ®Google Scholar
• Fukumoto Y, Shimokawa H. Rho-kinase inhibitors. In: Pharmacotherapy of pulmonary hypertension. Berlin: Springer; 2013. p. 351–364.
   Google Scholar
• Benisty JI, McLaughlin VV, Landzberg MJ, et al. Elevated basic fibroblast growth factor levels in patients with pulmonary arterial hypertension. Chest. 2004;126(4):1255–1261.
   PubMed Web of Science ®Google Scholar
• Tu L, De Man FS, Girerd B, et al. A critical role for p130Cas in the progression of pulmonary hypertension in humans and rodent. Am J Respir Crit Care Med. 2012;186(7):666–676.
   PubMed Web of Science ®Google Scholar
• Dahal BK, Cornitescu T, Tretyn A, et al. Role of epidermal growth factor inhibition in experimental pulmonary hypertension. Am J Respir Crit Care Med. 2010;181(2):158–167.
   PubMed Web of Science ®Google Scholar
• Shi J, Wei L. Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil. J Cardiovasc Pharmacol. 2013;62(4):1–32.
   PubMed Web of Science ®Google Scholar
• Uehata M, Ishizaki T, Satoh H, et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature. 1997;389:990–994.
   PubMed Web of Science ®Google Scholar
• Somlyo AP, Somlyo AV. Signal transduction by G-proteins, Rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II. J Physiol. 2000;522(2):177–185.
   PubMed Web of Science ®Google Scholar
• Do E Z, Fukumoto Y, Takaki A, et al. Evidence for Rho-kinase activation in patients with pulmonary arterial hypertension. Circ J. 2009;73:1731–1739.
   PubMed Web of Science ®Google Scholar
• Abe K, Shimokawa H, Morikawa K, et al. Long-term treatment with a rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res. 2004;94:385–393.
   PubMed Web of Science ®Google Scholar
• Fagan KA, Oka M, Bauer NR, et al. Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of rho-kinase. Am J Physiol Lung Cell Mol Physiol. 2004;287:L656–L664.
   PubMed Web of Science ®Google Scholar
• Guilluy C, Sauzeau V, Rolli-Derkinderen M, et al. Inhibition of RhoA/Rho-kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension. Br J Pharmacol. 2005;146:1010–1018.
   PubMed Web of Science ®Google Scholar
• Nagaoka T, Morio Y, Casanova N, et al. Rho/Rho-kinase signaling mediates increased basal pulmonary vascular tone in chronically hypoxic rats. Am J Physiol Lung Cell Mol Physiol. 2004;287:L665–L672.
   PubMed Web of Science ®Google Scholar
• Mouchaers KT, Schalij I, deBoer MA, et al. Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil. Eur Respir J. 2010;36:800–807.
   PubMed Web of Science ®Google Scholar
• Oka M, Homma N, Taraseviciene-Stewart L, et al. Rho-kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats. Circ Res. 2007;100:923–929.
   PubMed Web of Science ®Google Scholar
• Fukumoto Y, Matoba T, Ito A, et al. Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart. 2005;91:391–392.
   PubMed Web of Science ®Google Scholar
• Fukumoto Y, Yamada N, Matsubara H, et al. A double-blind, placebo-controlled clinical trial with a Rho-kinase inhibitor in pulmonary arterial hypertension; a pilot efficacy trial. Circ J. 2013;77:2691–2625.
   PubMed Web of Science ®Google Scholar

•• Fasudil, a Rho-kinase inhibitor, showed an improvement in the cardiac index in 20 PAH patients.

• Dempsie Y, Morecroft I, Welsh DJ, et al. Converging evidence in support of the serotonin hypothesis of dexfenfluramine-induced pulmonary hypertension with novel transgenic mice. Circulation. 2008;117:2928–2937.
   PubMed Web of Science ®Google Scholar
• Maclean MR, Dempsi Y. The serotonin hypothesis of pulmonary hypertension revisited. Adv Exp Med Biol. 2010;661:309–322.
   PubMed Web of Science ®Google Scholar
• Adnot S, Houssaini A, Abid S, et al. Serotonin transporter and serotonin receptors. In: Pharmacotherapy of pulmonary hypertension. Berlin: Springer; 2013. p. 365–380.
   Google Scholar
• Izikki M, Hanoun N, Marcos E, et al. Tryptophan hydroxylase 1 knockout and tryptophan hydroxylase 2 polymorphism: effects on hypoxic pulmonary hypertension in mice. Am J Physiol Lung Cell Mol Physiol. 2007;293:L1045–L1052.
   PubMed Web of Science ®Google Scholar
• Morecroft I, Dempsie Y, Bader M, et al. Effect of tryptophan hydroxylase 1 deficiency on the development of hypoxia-induced pulmonary hypertension. Hypertension. 2007;49:232–236.
   PubMed Web of Science ®Google Scholar
• Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International primary pulmonary hypertension study group. N Engl J Med. 1996;335:609–616.
   PubMed Web of Science ®Google Scholar
• Herve P, Launay JM, Scrobahaci ML, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med. 1995;99:249–254.
   PubMed Web of Science ®Google Scholar
• Eddahibi S, Humbert M, Fadel E, et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest. 2001;108:1141–1150.
   PubMed Web of Science ®Google Scholar
• Fanburg B, Lee SL. A new role for an old molecule: serotonin as a mitogen. Am J Physiol. 1997;272:L795–L806.
   PubMed Web of Science ®Google Scholar
• Eddahibi S, Hanoun N, Lanfumey L, et al. Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J Clin Invest. 2000;105:1555–1562.
   PubMed Web of Science ®Google Scholar
• Guignabert C, Raffestin B, Benferhat R, et al. Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation. 2005;111:2812–2819.
   PubMed Web of Science ®Google Scholar
• MacLean MR, Deuchar GA, Hicks MN, et al. Overexpression of the 5-hydroxytryptamine transporter gene: effect on pulmonary hemodynamics and hypoxia-induced pulmonary hypertension. Circulation. 2004;109:2150–2155.
   PubMed Web of Science ®Google Scholar
• Guilluy C, Eddahibi S, Agard C, et al. RhoA and Rho kinase activation in human pulmonary hypertension: role of 5-HT signaling. Am J Respir Crit Care Med. 2009;179(12):1151–1158.
   PubMed Web of Science ®Google Scholar
• Ren W, Watts SW, Fanburg BL. Serotonin transporter interacts with the PDGFbeta receptor in PDGF-BB-induced signaling and mitogenesis in pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2011;300:L486–L497.
   PubMed Web of Science ®Google Scholar
• Liu Y, Li M, Warburton RR, et al. The 5-HT transporter transactivates the PDGFbeta receptor in pulmonary artery smooth muscle cells. FASEB J. 2007;21:2725–2734.
   PubMed Web of Science ®Google Scholar
• Kren V, Eich E, Pertz HH. Pergolide, terguride and N,N′-spacerlinked oligomers of both interact with 5-HT2A receptors of rat tail artery. Physiol Res. 2004;53:35–43.
   PubMed Web of Science ®Google Scholar
• Millan MJ, Maiofiss L, Cussac D, et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther. 2002;303:791–804.
   PubMed Web of Science ®Google Scholar
• Jahnichen S, Horowski R, Pertz HH. Agonism at 5-HT2B receptors is not a class effect of the ergolines. Eur J Pharmacol. 2005;513:225–228.
   PubMed Web of Science ®Google Scholar
• Dumitrascu R, Kulcke C, Konigshoff M, et al. Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats. Eur Respir J. 2011;37(5):1104–1118.
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Al-Hiti H, Vonk-Noordegraaf A, et al. Proof-of-concept study to investigate the efficacy, hemodynamics and tolerability of terguride vs. placebo in subjects with pulmonary arterial hypertension: results of a double blind, randomised, prospective Phase 2a study. Am J Respir Crit Care Med. 2012;185:A2496.
   Google Scholar
• Abid S, Houssaini A, Chevarin C, et al. Inhibition of gut- and lung-derived serotonin attenuates pulmonary hypertension in mice. Am J Physiol Lung Cell Mol Physiol. 2012;303:L500–L508.
   PubMed Web of Science ®Google Scholar
• Price LC, Wort SJ, Perros F, et al. Inflammation in pulmonary arterial hypertension. Chest. 2012;141:210–221.
   PubMed Web of Science ®Google Scholar

• This article reviews the evidence to support the role of various inflammatory cells and mediators in PAH.

• Perros F, Dorfmuller P, Montani D, et al. Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012;185:311–321.
   PubMed Web of Science ®Google Scholar
• Bokhari S, Raina A, Berman Rosenweig E, et al. PET imaging may provide a novel biomarker and understanding of right ventricular dysfunction in patients with idiopathic pulmonary arterial hypertension. Circ Cardiovasc Imaging. 2011;4:641–647.
   PubMed Web of Science ®Google Scholar

• This study provided an indirect evidence for right ventricular metabolic switch in PAH patients with the use of PET imaging.

• Niu X, Nouraie M, Campbell A, et al. Angiogenic and inflammatory markers of cardiopulmonary changes in children and adolescents with sickle cell disease. PLoS One. 2009;4:e7956.
   PubMed Web of Science ®Google Scholar
• Meloche J, Renard S, Provencher S, et al. Anti-inflammatory and immunosuppressive agents in PAH. In: Pharmacotherapy of pulmonary hypertension. Berlin: Springer; 2013. p. 437–476.
   Google Scholar
• Taraseviciene-Stewart L, Nicolls MR, Kraskauskas D, et al. Absence of T cells confers increased pulmonary arterial hypertension and vascular remodeling. Am J Respir Crit CareMed. 2007;175:1280–1289.
   PubMed Web of Science ®Google Scholar
• Dahal BK, Kosanovic D, Kaulen C, et al. Involvement of mast cells in monocrotaline-induced pulmonary hypertension in rats. Respir Res. 2011;12(60):38.
   PubMed Web of Science ®Google Scholar
• Savale L, Tu L, Rideau D, et al. Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice. Respir Res. 2009;10(6):236–244.
   Google Scholar
• Gourh P, Arnett FC, Assassi S, et al. Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations. Arthritis Res Ther. 2009;11:R147.
   PubMed Web of Science ®Google Scholar
• Steiner MK, Syrkina OL, Kolliputi N, et al. Interleukin-6 overexpression induces pulmonary hypertension. Circ Res. 2009;104(2):236–244.
   PubMed Web of Science ®Google Scholar
• Soon E, Holmes AM, Treacy CM, et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation. 2010;122:920–927.
   PubMed Web of Science ®Google Scholar

• This study demonstrated the impact of inflammatory cytokines on 5-year survival in PAH patients.

• Price LC, Montani D, Tcherakian C, et al. Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats. Eur Respir J. 2011;37:813–822.
   PubMed Web of Science ®Google Scholar
• Ogawa A, Nakamura K, Matsubara H, et al. Prednisolone inhibits proliferation of cultured pulmonary artery smooth muscle cells of patients with idiopathic pulmonary arterial hypertension. Circulation. 2005;112:1806–1812.
   PubMed Web of Science ®Google Scholar
• Jais X, Launay D, Yaici A, et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum. 2008;58(2):521–531.
   PubMed Web of Science ®Google Scholar
• Sanchez O, Sitbon O, Jais X, et al. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. CHEST J. 2006;130(1):182–189.
   PubMed Web of Science ®Google Scholar
• Miyamichi-Yamamoto S, Fukumoto Y, Sugimura K, et al. Intensive immunosuppressive therapy improves pulmonary hemodynamics and long-term prognosis in patients with pulmonary arterial hypertension associated with connective tissue disease. Circ J. 2011;75(11):2668–2674.
   PubMed Web of Science ®Google Scholar
• Alzoubi A, Toba M, Abe K, et al. Dehydroepiandrosterone restores right ventricular structure and function in rats with severe pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol. 2013;304(12):H1708–H1718.
   PubMed Web of Science ®Google Scholar
• Paulin R, Meloche J, Jacob MH, et al. Dehydroepiandrosterone inhibits the Src/STAT3constitutive activation in pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol. 2011;301:H1798–H1809.
   PubMed Web of Science ®Google Scholar
• Bellotto F, Chiavacci P, Laveder F, et al. Effective immunosuppressive therapy in a patient with primary pulmonary hypertension. Thorax. 1999;54(4):372–374.
   PubMed Web of Science ®Google Scholar
• Grossi O, Horeau-Langlard D, Agard C, et al. Low-dose methotrexate in PAH related to T-cell large granular lymphocyte leukaemia. Eur Respir J. 2012;39(2):493–494.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Li M, Zhang Y, et al. The effects and mechanisms of mycophenolate mofetil on pulmonary arterial hypertension in rats. Rheumatol Int. 2010;30(3):341–348.
   PubMed Web of Science ®Google Scholar
• Wang Q, Zuo XR, Wang YY, et al. Monocrotaline-induced pulmonary arterial hypertension is attenuated by TNF-α antagonists via the suppression of TNF-α expression and NF-κB pathway in rats. Vascul Pharmacol. 2013;58(1):71–77.
   PubMed Web of Science ®Google Scholar
• Mutschler D, Wikstrom G, Lind L, et al. Etanercept reduces late endotoxin-induced pulmonary hypertension in the pig. J Interferon Cytokine Res. 2006;26(9):661–667.
   PubMed Web of Science ®Google Scholar
• Bonnet S, Rochefort G, Sutendra G, et al. The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. Proc Natl Acad Sci USA. 2007;104:11418–11423.
   PubMed Web of Science ®Google Scholar
• Houssaini A, Abid S, Mouraret N, et al. Rapamycin reverses pulmonary artery smooth muscle cell proliferation in pulmonary hypertension. Am J Respir Cell Mol Biol. 2013;48(5):568–577.
   PubMed Web of Science ®Google Scholar
• McMurtry MS, Bonnet S, Michelakis E, et al. Statin therapy, alone or with rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: the rapamcyin–atorvastatin–simvastatin study. Am J Physiol Lung Cell Mol Physiol. 2007;293(4):L933–L940.
   PubMed Web of Science ®Google Scholar
• Wessler JD, Steingart RM, Schwartz GK, et al. Dramatic improvement in pulmonary hypertension with rapamycin. Chest Journal. 2010;138(4):991–993.
   PubMed Web of Science ®Google Scholar
• Mizuno S, Farkas L, Al Husseini A, et al. Severe pulmonary arterial hypertension induced by SU5416 and ovalbumin immunization. Am J Respir Cell Mol Biol. 2012;47(5):679–687.
   PubMed Web of Science ®Google Scholar
• Padilla-Ibarra J, Sanchez-Ortiz A, Sandoval-Castro C, et al. Rituximab treatment for pulmonary arterial hypertension in adult-onset Still’s disease. Clin Exp Rheumatol. 2013;31(4):657.
   PubMed Web of Science ®Google Scholar
• Hennigan S, Channick RN, Silverman GJ. Rituximab treatment of pulmonary arterial hypertension associated with systemic lupus erythematosus: a case report. Lupus. 2008;17(8):754–756.
   PubMed Web of Science ®Google Scholar
• Taniguchi K, Shimazaki C, Fujimoto Y, et al. Tocilizumab is effective for pulmonary hypertension associated with multicentric Castleman’s disease. Int J Hematol. 2009;90(1):99–102.
   PubMed Web of Science ®Google Scholar
• Arita Y, Sakata Y, Sudo T, et al. The efficacy of tocilizumab in a patient with pulmonary arterial hypertension associated with Castleman’s disease. Heart Vessels. 2010;25(5):444–447.
   PubMed Web of Science ®Google Scholar
• Kadavath S, Zapantis E, Zolty R, et al. A novel therapeutic approach in pulmonary arterial hypertension as a complication of adult-onset Still’s disease: targeting IL-6. Int J Rheum Dis. 2014;17(3):336–340.
   PubMed Web of Science ®Google Scholar
• Heath D, Yacoub M. Lung mast cells in plexogenic pulmonary arteriopathy. J Clin Pathol. 1991;44:1003–1006.
   PubMed Web of Science ®Google Scholar
• Farha S, Sharp J, Asosingh K, et al. Mast cell number, phenotype, and function in human pulmonary arterial hypertension. Pulm Circ. 2012;2(2):220.
   PubMedGoogle Scholar

•• This study looked at the markers of mast cell activity in PAH patients and the effects of mast cell stabilizer/antihistaminic combination therapy in these patients.

• Leary PJ, Barr RG, Bluemke DA, et al. H2 receptor antagonists and right ventricular morphology: the MESA right ventricle study. Ann Am Thorac Soc. 2014;11(9):1379–1386.
   PubMedGoogle Scholar
• Tabima DM, Frizzell S, Gladwin MT. Reactive oxygen and nitrogen species in pulmonary hypertension. Free Radic Biol Med. 2012;52(9):1970–1986.
   PubMed Web of Science ®Google Scholar
• Demoncheaux EA, Kielyb DG, Richard JM, et al. Decreased whole body endogenous nitric oxide production in patients with primary pulmonary hypertension. J Vasc Res. 2005;42(2):133–136.
   PubMed Web of Science ®Google Scholar
• Weerackody RP, Welsh DJ, Wadsworth RM, et al. Inhibition of p38 MAPK reverses hypoxia-induced pulmonary artery endothelial dysfunction. Am J Physiol Heart Circ Physiol. 2009;296(5):H1312–H1320.
   PubMed Web of Science ®Google Scholar
• Khoo JP, Zhao L, Alp NJ, et al. Pivotal role for endothelial tetrahydrobiopterin in pulmonary hypertension. Circulation. 2005;111(16):2126–2133.
   PubMed Web of Science ®Google Scholar
• Wunderlich C, Schober K, Schmeisseret A, et al. The adverse cardiopulmonary phenotype of caveolin-1deficient mice is mediated by a dysfunctional endothelium. J Mol Cell Cardiol. 2008;44(5):938–947.
   PubMed Web of Science ®Google Scholar
• Morris CR, Gladwin MT, Kato GJ. Nitric oxide and arginine dysregulation: a novel pathway to pulmonary hypertension in hemolytic disorders. Curr Mol Med. 2008;8(7):620–632.
   PubMed Web of Science ®Google Scholar
• De Castro LM, Jonassaint JC, Graham FL, et al. Pulmonary hypertension associated with sickle cell disease: clinical and laboratory endpoints and disease outcomes. Am J Hematol. 2008;83(1):19–25.
   PubMed Web of Science ®Google Scholar
• Risbano MG, Gladwin MT. Therapeutics targeting of dysregulated redox equilibrium and endothelial dysfunction. In: Pharmacotherapy of Pulmonary Hypertension. Berlin: Springer; 2013. p. 315–349.
   Google Scholar
• DeMarco VG, Habibi J, Whaley-Connell AT, et al. Oxidative stress contributes to pulmonary hypertension in the transgenic (mRen2)27 rat. Am J Physiol Heart Circ Physiol. 2008;294(6):H2659–H2668.
   PubMed Web of Science ®Google Scholar
• Barst RJ, Channick R, Ivy D, et al. Clinical perspectives with long-term pulsed inhaled nitric oxide for the treatment of pulmonary arterial hypertension. Pulm Circ. 2012;2(2):139.
   PubMedGoogle Scholar
• Ivy DD, Parker D, Doran A, et al. Acute hemodynamic effects and home therapy using a novel pulsed nasal nitric oxide delivery system in children and young adults with pulmonary hypertension. Am J Cardiol. 2003;92:886–890.
   PubMed Web of Science ®Google Scholar
• Lundberg JO, Weitzberg E, Gladwin MT. The nitrate–nitrite–nitric oxide pathway in physiology and therapeutics. Nat Rev Drug Discov. 2008;7:156–167.
   PubMed Web of Science ®Google Scholar

•• This seminal paper reviews various mediators involved in the nitrate–nitrite–nitric oxide pathway in humans.

• Brandler MD, Powell SC, Craig DM, et al. A novel inhaled organic nitrate that affects pulmonary vascular tone in a piglet model of hypoxia-induced pulmonary hypertension. Pediatr Res. 2005;58:531–536.
   PubMed Web of Science ®Google Scholar
• Young KC, Ladino J, Navarrete C, et al. The effect of a nebulized NO donor, DPTA/NO, on acute hypoxic pulmonary hypertension in newborn piglets. Biol Neonate. 2004;85:195–202.
   PubMedGoogle Scholar
• Hampl V, Tristani-Firouzi M, Hutsell TC, et al. Nebulized nitric oxide/nucleophile adduct reduces chronic pulmonary hypertension. Cardiovasc Res. 1996;31(1):55–62.
   PubMed Web of Science ®Google Scholar
• Baliga RS, Milsom AB, Ghosh SM, et al. Dietary nitrate ameliorates pulmonary hypertension cytoprotective role for endothelial nitric oxide synthase and xanthine oxidoreductase. Circulation. 2012;125(23):2922–2932.
   PubMed Web of Science ®Google Scholar
• Kunuthur SP, Milliken PH, Gibson CL, et al. Tetrahydrobiopterin analogues with NO-dependent pulmonary vasodilator properties. Eur J Pharmacol. 2011;650(1):371–377.
   PubMed Web of Science ®Google Scholar
• Teng RJ, Du J, Xu H, et al. Sepiapterin improves angiogenesis of pulmonary artery endothelial cells with in utero pulmonary hypertension by recoupling endothelial nitric oxide synthase. Am J Physiol Lung Cell Mol Physiol. 2011;301(3):L334–L345.
   PubMed Web of Science ®Google Scholar
• Robbins IM, Hemnes AR, Gibbs JS, et al. Safety of sapropterin dihydrochloride (6r-bh4) in patients with pulmonary hypertension. Exp Lung Res. 2011;37(1):26–34.
   PubMed Web of Science ®Google Scholar
• Kalinowski L, Dobrucki IT, Malinski T. Cicletanine stimulates nitric oxide release and scavenges superoxide in endothelial cells. J Cardiovasc Pharmacol. 2001;37(6):713–724.
   PubMed Web of Science ®Google Scholar
• Waxman AB, Lawler L, Cornett G. Cicletanine for the treatment of pulmonary arterial hypertension. Arch Intern Med. 2008;168(19):2164–2166.
   PubMed Web of Science ®Google Scholar
• Waxman AB, Oudiz R, Shapiro S, et al. Cicletanine in pulmonary arterial hypertension (PAH): results from a phase 2 randomized placebo-controlled trial. Eur Respir J. 2012;40(Suppl 56):3274.
   Google Scholar
• Howell K, Costello CM, Sands M, et al. L-Arginine promotes angiogenesis in the chronically hypoxic lung: a novel mechanism ameliorating pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2009;296(6):L1042–L1050.
   PubMed Web of Science ®Google Scholar
• Mehta S, Stewart DJ, Langleben D, et al. Short-term pulmonary vasodilation with L-arginine in pulmonary hypertension. Circulation. 1995;92(6):1539–1545.
   PubMed Web of Science ®Google Scholar
• Nagaya N, Uematsu M, Oya H, et al. Short-term oral administration of L-arginine improves hemodynamics and exercise capacity in patients with precapillary pulmonary hypertension. Am J Respir Crit Care Med. 2001;163(4):887–891.
   PubMed Web of Science ®Google Scholar
• Ahmed LA, Al Arqam ZO, Zaki HF, et al. Naringenin adds to the protective effect of L-arginine in monocrotaline-induced pulmonary hypertension in rats: favorable modulation of oxidative stress, inflammation and nitric oxide. Eur J Pharm Sci. 2014;62:161–170.
   PubMed Web of Science ®Google Scholar
• Archer SL, Marsboom G, Kimet GH, et al. Epigenetic attenuation of mitochondrial superoxidedismutase 2 in pulmonary arterial hypertension: a basis for excessive cell proliferation and a new therapeutic target. Circulation. 2010;121(24):2661–2671.
   PubMed Web of Science ®Google Scholar
• Villegas LR, Kluck D, Field C, et al. Superoxide dismutase mimetic, MnTE-2-PyP, attenuates chronic hypoxia-induced pulmonary hypertension, pulmonary vascular remodeling, and activation of the NALP3 inflammasome. Antioxid Redox Signal. 2013;18(14):1753–1764.
   PubMed Web of Science ®Google Scholar
• Hemnes AR, Zaiman A, Champion HC. PDE5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/Rho kinase activation. Am J Physiol Lung Cell Mol Physiol. 2008;294(1):L24–L33.
   PubMed Web of Science ®Google Scholar
• DeMarco VG, Habibi J, Whaley-Connell AT, et al. Rosuvastatin ameliorates the development of pulmonary arterial hypertension in the transgenic (mRen2) 27 rat. Am J Physiol Heart Circ Physiol. 2009;297(3):H1128–H1139.
   PubMed Web of Science ®Google Scholar
• Mittal M, Roth M, König K, et al. Hypoxia-dependent regulation of nonphagocytic NADPH oxidase subunit NOX4 in the pulmonary vasculature. Circ Res. 2007;101(3):258–267.
   PubMed Web of Science ®Google Scholar
• Seta F, Rahmani M, Turner PV, et al. Pulmonary oxidative stress is increased in cyclooxygenase-2 knockdown mice with mild pulmonary hypertension induced by monocrotaline. Plos One. 2011;6(8):e23439.
   PubMed Web of Science ®Google Scholar
• Zhang D, Wang G, Han D, et al. Activation of PPAR-γ ameliorates pulmonary arterial hypertension via inducing heme oxygenase-1 and p21 WAF1: an in vivo study in rats. Life Sci. 2014;98(1):39–43.
   PubMed Web of Science ®Google Scholar
• Camer D, Yu Y, Szaboet A, et al. The molecular mechanisms underpinning the therapeutic properties of oleanolic acid, its isomer and derivatives for type 2 diabetes and associated complications. Mol Nutr Food Res. 2014;58(8):1750–1759.
   PubMed Web of Science ®Google Scholar
• Chin MP, Wrolstad D, Bakris GL, et al. Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with Bardoxolone Methyl. J Card Fail. 2014;20(12):953–958.
   PubMed Web of Science ®Google Scholar
• Benhar M, Stamler JS. A central role for S-nitrosylation in apoptosis. Nat Cell Biol. 2005;7(7):645–646.
   PubMed Web of Science ®Google Scholar
• Wu X, Du L, Xu X, et al. Increased nitrosoglutathione reductase activity in hypoxic pulmonary hypertension in mice. J Pharmacol Sci. 2010;113(1):32–40.
   PubMed Web of Science ®Google Scholar
• Blonder JP, Mutka SC, Sun X, et al. Pharmacologic inhibition of S-nitrosoglutathione reductase protects against experimental asthma in BALB/c mice through attenuation of both bronchoconstriction and inflammation. BMC Pulm Med. 2014;14(1):3.
   PubMed Web of Science ®Google Scholar
• Peacock A, Ross K. Pulmonary hypertension: a contraindication to the use of β-adrenoceptor blocking agents. Thorax. 2010;65:454–455.
   PubMed Web of Science ®Google Scholar
• Provencher S, Herve P, Jais X, et al. Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology. 2006;130:120–126.
   PubMed Web of Science ®Google Scholar
• Watson G, Oliver E, Zhao L, et al. Pulmonary hypertension: old targets revisited (statins, PPARs, beta-blockers).In: Pharmacotherapy of pulmonary hypertension. Berlin: Springer; 2013. p. 531–548.
   Google Scholar
• Bogaard HJ, Natarajan R, Mizuno S, et al. Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats. Am J Respir Crit Care Med. 2010;182:652–660.
   PubMed Web of Science ®Google Scholar
• So PPS, Davies RA, Chandy G, et al. Usefulness of beta-blocker therapy and outcomes in patients with pulmonary arterial hypertension. Am J Cardiol. 2012;109:1504–1509.
   PubMed Web of Science ®Google Scholar
• Thenappan T, Roy SS, Duval S, et al. Beta-blocker therapy is not associated with adverse outcomes in patients with pulmonary arterial hypertension: a propensity score analysis. Circ Heart Fail. 2014;7(6):903–910.
   PubMed Web of Science ®Google Scholar

• This large retrospective analysis showed no change in long-term mortality with the use of beta-blockers in PAH patients.

• Grinnan D, Bogaard HJ, Grizzardet J, et al. Treatment of group I pulmonary arterial hypertension with carvedilol is safe. Am J Respir Crit Care Med. 2014;189(12):1562–1564.
   PubMed Web of Science ®Google Scholar
• De Boer K, Wagenaar M, Handoko M, et al. Beta-blocker therapy in patients with idiopathic pulmonary arterial hypertension: a randomized controlled trial. Am J Respir Crit Care Med. 2014;189:A6569.
   Google Scholar
• Martyniuk TV, Konosova ID, Chazova IE, et al. Use of nebivolol in patients with idiopathic pulmonary hypertension: results of the pilot study. Ter Arkh. 2011;84(12):49–53.
   Web of Science ®Google Scholar
• Perros F, Ranchoux B, Izikki M, et al. Nebivolol for improving endothelial dysfunction, pulmonary vascular remodeling, and right heart function in pulmonary hypertension. J Am Coll Cardiol. 2015;65(7):668–680.
   PubMed Web of Science ®Google Scholar
• Crossno JT, Garat CV, Reusch JEB, et al. Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling. Am J Physiol Lung Cell Mol Physiol. 2007;292:L885–L897.
   PubMed Web of Science ®Google Scholar
• Ameshima S, Golpon H, Cool CD, et al. Peroxisome proliferator-activated receptor gamma expression is decreased in pulmonary hypertension and affects endothelial cell growth. Circ Res. 2003;30(92):1162–1169.
   Web of Science ®Google Scholar
• Harrington LS, Moreno L, Reed A. et al. The PPARbeta/delta agonist GW0742 relaxes pulmonary vessels and limits right heart hypertrophy in rats with hypoxia-induced pulmonary hypertension. PLoS One. 2010;5:e9526.
   PubMed Web of Science ®Google Scholar
• Girgis RE, Li D, Zhan X, et al. Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Heart Circ Physiol. 2003;285(3):H938–H945.
   PubMed Web of Science ®Google Scholar
• Nishimura T, Vaszar LT, Faul JL, et al. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation. 2003;108(13):1640–1645.
   PubMed Web of Science ®Google Scholar
• Taraseviciene-Stewart L, Scerbavicius R, Choe KH, et al. Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2006;291(4):L668–L676.
   PubMed Web of Science ®Google Scholar
• Zhao L, Sebkhi A, Ali O, et al. Simvastatin and sildenafil combine to attenuate pulmonary hypertension. Eur Respir J. 2009;34(4):948–957.
   PubMed Web of Science ®Google Scholar
• Kao PN. Simvastatin treatment of pulmonary hypertension: an observational case series. Chest. 2005;127:1446–1452.
   PubMed Web of Science ®Google Scholar
• Wilkins MR, Ali O, Bradlow W, et al. Simvastatin as a treatment for pulmonary hypertension trial. Am J Respir Crit Care Med. 2010;181:1106–1113.
   PubMed Web of Science ®Google Scholar
• Kawut SM, Bagiella E, Lederer DJ, et al. Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension: ASA-STAT. Circulation. 2011;123:2985–2993.
   PubMed Web of Science ®Google Scholar
• Dromparis P, Michelakis ED. Mitochondria in health and disease. Annu Rev Physiol. 2013;75:95–106.
   PubMed Web of Science ®Google Scholar
• Dromparis P, Paulin R, Stenson TH, et al. Attenuating endoplasmic reticulum stress as a novel therapeutic strategy in pulmonary hypertension. Circulation. 2013;127(1):115–125.
   PubMed Web of Science ®Google Scholar
• McMurtry MS, Bonnet S, Wu X, et al. Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ Res. 2004;95:830–840.
   PubMed Web of Science ®Google Scholar
• Archer SL, Fang YH, Ryan JJ, et al. Metabolism and bioenergetics in the right ventricle and pulmonary vasculature in pulmonary hypertension. Pulm Circ. 2013;3(1):144–152.
   PubMedGoogle Scholar
• Michelakis ED, McMurtry MS, Wu XC, et al. Dichloroacetate, a metabolic modulator prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltage-gated potassium channels. Circulation. 2002;105:244–250.
   PubMed Web of Science ®Google Scholar
• Tuunanen H, Engblom E, Naum A, et al. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circ. 2008;118:1250–1258.
   PubMed Web of Science ®Google Scholar
• Sutendra G, Bonnet S, Rochefort G, et al. Fatty acid oxidation and malonyl-CoA decarboxylase in the vascular remodeling of pulmonary hypertension. Sci Transl Med. 2010;238(2):44ra58.
   Google Scholar
• Bonnet S, Michelakis ED, Porter CJ, et al. An abnormal mitochondrial-hypoxia inducible factor-1α-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: similarities to human pulmonary arterial hyper- tension. Circulation. 2006;113:2630–2641.
   PubMed Web of Science ®Google Scholar
• Liles JT, Hoyer K, Oliver J, et al. Ranolazine reduces remodeling of the right ventricle and provoked arrhythmias in rats with pulmonary hypertension. J Pharmacol Exp Ther. 2015;353:480–489.
   PubMed Web of Science ®Google Scholar
• Koyama M, Furuhashi M, Ishimura S, et al. Reduction of endoplasmic reticulum stress by 4-phenylbutyric acid prevents the development of hypoxia-induced pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol. 2014;306(9):H1314–H1323.
   PubMed Web of Science ®Google Scholar
• Yeager ME, Reddy MB, Nguyen CM, et al. Activation of the unfolded protein response is associated with pulmonary hypertension. Pulm Circ. 2012;2(2):229–240.
   PubMedGoogle Scholar
• Saco TV, Parthasarathy PT, Cho Y, et al. Role of epigenetics in pulmonary hypertension. Am J Physiol Cell Physiol. 2014;306(12):C1101–C1105.
   PubMed Web of Science ®Google Scholar
• Kim GH, Ryan JJ, Marsboom G, et al. Epigenetic mechanisms of pulmonary hypertension. Pulm Circ. 2011;1:347–356.
   PubMedGoogle Scholar
• Cho YK, Eom GH, Kee HJ, et al. Sodium valproate, a histone deacetylase inhibitor, but not captopril, prevents right ventricular hypertrophy in rats. Circ J. 2010;74:760–770.
   PubMed Web of Science ®Google Scholar
• Bogaard HJ, Mizuno S, Hussaini AAA, et al. Suppression of histone deacetylases worsens right ventricular dysfunction after pulmonary artery banding in rats. Am J Respir Crit Care Med. 2011;183:1402–1410.
   PubMed Web of Science ®Google Scholar
• Cavasin MA, Demos-Davies K, Horn TR, et al. Selective class I histone deacetylase inhibition suppresses hypoxia-induced cardiopulmonary remodeling through an antiproliferative mechanism. Circ Res. 2012;110:739–748.
   PubMed Web of Science ®Google Scholar
• Kim J, Kang Y, Kojima Y, et al. An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension. Nat Med. 2013;19(120):74–82.
   PubMed Web of Science ®Google Scholar
• Foster WS, Suen CM, Stewart DJ. Regenerative cell and tissue based therapies for PAH. Can J Cardiol. 2014;30:1350–1360.
   PubMed Web of Science ®Google Scholar
• Zhu JH, Wang XX, Zhang FR, et al. Safety and efficacy of autologous endothelial progenitor cells transplantation in children with idiopathic pulmonary arterial hypertension: open-label pilot study. Pediatr Tranplant. 2008;12(6):650–655.
   PubMed Web of Science ®Google Scholar